Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial-Reference-Cited by-同舟云学术

Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial

Published:2005-06 Issue:16_suppl Volume:23 Page:3630-3630
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Adenis A.¹,Aranda Aguilar E.¹,Robin Y. M.¹,Miquel R.¹,Penault-Llorca F.¹,Castañón C.¹,Queralt B.¹,Eggleton S. P.¹,van den Berg N.¹,Wilke H.¹

Affiliation:

1. Ctr Oscar Lambret, Lille, France; Hosp Provincial Reina Sofia, Córdoba, Spain; Hosp Clinic i Provincial de Barcelona, Barcelona, Spain; Ctr Jean Perrin, Clermont Ferrand, France; Hosp Virgen Blanca de León, León, Spain; Inst Catala d’Oncologia, Girona, Spain; Merck KGaA, Darmstadt, Germany; Klin Essen Mite, Essen, Germany

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.3630

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials;Cancer Chemotherapy and Pharmacology;2009-08-13

2. Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer;Journal of Clinical Oncology;2009-02-10

3. Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study;Journal of Clinical Oncology;2008-11-20

4. Urgent Need for a New Staging System in Advanced Colorectal Cancer;Journal of Clinical Oncology;2008-10-10

5. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group;Annals of Oncology;2008-08